1. Mitigating Infection Risk With DMT in MS

2. Evolving Therapeutic Landscape in MS

3. Potential for Infectious Risk With Maintenance Therapy vs IRT

4. Selectivity of Infectious Agents According to the Nature of Immunosuppression

5. Listeria Infection With Alemtuzumab

6. Herpes Zoster Infection

7. VZV Vaccination

8. PML Surveillance in Patients Treated With Natalizumab

9. HPV Infection

10. Screening for Infections Before Starting DMTs

11. Immunoglobulin Levels and Infection Risk With Anti-CD20 mAbs

12. Vaccinating Against Encapsulated Bacteria

13. Use of Live Vaccines

14. Use of Prophylactic Anti-Infective Agents

15. Extended-Interval Dosing of Natalizumab to Reduce PML Risk

16. PLEX to Accelerate Natalizumab Clearance and Limit PML Infection

17. Rare Infections With Fingolimod

18. Infections With DMF

19. Infections With Cladribine

20. Infections With Ocrelizumab

21. Conclusions

22. Abbreviations

23. Abbreviations (cont)